http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shiro Nakamura,Teita Asano,Hiroaki Tsuchiya,Kanami Sugimoto,Yuya Imai,Seiji Yokoyama,Yasuo Suzuki 대한장연구학회 2022 Intestinal Research Vol.20 No.3
Background/Aims: Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS.Methods: Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6.Results: Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population.Conclusions: The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.
GLOBAL DEPLOYMENT OF MITSUBISHI APWR, A GEN-III+ SOLUTION TO WORLD-WIDE NUCLEAR RENAISSANCE
Suzuki, Shigemitsu,Ogata, Yoshiki,Nishihara, Yukio,Fujita, Shiro Korean Nuclear Society 2009 Nuclear Engineering and Technology Vol.41 No.8
We at Mitsubishi have lined up Gen-III+ solutions for a wide variety of global customers: ATMEA1 of the 1100MWe class, and an APWR with the largest capacity of 1700MWe. In this paper, we would like to introduce the APWR. With an increased requirement for nuclear power generation as an effective countermeasure against global warming, we have established the APWR plant, a large-capacity Mitsubishi standard reactor combining our accumulated experience and technology as an integrated PWR plant supplier. The APWR plant has achieved high reliability, safety and enhanced economy based on a technology that has been developed with the support of the government and utilities through improvement and standardization programs of light water reactors. Currently, Tsuruga Units 3 and 4, the first two APWRs, are undergoing licensing, while we are making efforts to obtain the standard design certification (DC) of US-APWR and preparing for the European Utility Requirements (EUR) compliance assessment of EU-APWR. Mitsubishi Heavy Industries, Ltd. (MHI) positions the APWR as a core technology that will contribute to the prevention of global warming and meet worldwide requirements.
Global Deployment of Mitsubishi APWR, a Gen-III+ Solution to the World-Wide Nuclear Renaissance
SHIGEMITSU SUZUKI,YOSHIKI OGATA,YUKIO NISHIHARA,SHIRO FUJITA 한국원자력학회 2009 Nuclear Engineering and Technology Vol.41 No.8
We at Mitsubishi have lined up Gen-III+ solutions for a wide variety of global customers: ATMEA1 of the 1100MWe class ,and an APWR with the largest capacity of 1700MWe. In this paper, we would like to introduce the APWR. With an increased requirement for nuclear power generation as an effective countermeasure against global warming, we have established the APWR plant, a large-capacity Mitsubishi standard reactor combining our accumulated experience and technology as an integrated PWR plant supplier. The APWR plant has achieved high reliability, safety and enhanced economy based on a technology that has been developed with the support of the government and utilities through improvement and standardization programs of light water reactors. Currently, Tsuruga Units 3 and 4, the first two APWRs, are undergoing licensing, while we are making efforts to obtain the standard design certification (DC) of US-APWR and preparing for the European Utility Requirements (EUR) compliance assessment of EU-APWR. Mitsubishi Heavy Industries, Ltd. (MHI) positions the APWR as a core technology that will contribute to the prevention of global warming and meet worldwide requirements.
Hiroaki Kajiyama,Shiro Suzuki,Nobuhisa Yoshikawa,Satoshi Tamauchi,Kiyosumi Shibata,Fumitaka Kikkawa 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.4
Objective: The impact of systematic retroperitoneal lymphadenectomy (SRL) remainscontroversial in patients with advanced ovarian clear-cell carcinoma (CCC) who areoptimally debulked. Methods: Between 1986 and 2017, a total of 3,227 women with epithelial ovarian carcinomawere analyzed in a multi-institutional study. Among them, 166 optimally debulked womenwith stage IIB–IV CCC were collected (residual tumor of <1 cm). All patients were divided into2 groups: 1) Group I (n=112): underwent standard radical surgery with SRL, 2) Group II (n=54):underwent non-staging limited surgery. The pathological slides were assessed based on centralpathological review. Oncologic outcomes were compared between the two groups using apropensity score (PS)-matching technique to adjust for various clinicopathologic factors. Results: The median follow-up duration of all surviving women was 52.8 (1.6–184.2) months. Overall, 88 patients (53.0%) experienced recurrence and 68 patients (41.0%) died of thedisease. In the original cohort, the 5-year overall survival (OS) rates of groups I and II were57.9 and 64.9%, respectively (log-rank p=0.415). In the PS-adjusted cohort, the 5-year OSrates were 64.9 and 58.8% in women in groups I and II, respectively (p=0.453). Furthermore,in the PS-matched cohort after adjustment for multiple clinicopathologic factors, there wasno significant difference in OS between the 2 groups (group I vs. group II; hazard ratio=1.170;95% confidence interval=0.633–2.187; p=0.615). Conclusions: This study suggests that the performance of SRL including radical surgery maynot lead to a significant improvement in the oncologic outcome of advanced CCC patientswith optimal cytoreduction.
비정질 Se 광도전 타겟을 이용한 고감도 HARP 촬상관의 제작 및 특성
박욱동,김기완,Kubota, M.,Suzuki, S.,Katoh, T.,Tanioka, K. 경북대학교 센서기술연구소 1997 센서技術學術大會論文集 Vol.8 No.1
A high sensitivity HARP(High-gain Avalanche Rushing amorphous Photoconductor) image pickup tube using 4 μm thick amorphous Se photoconductive target was fabricated and its characteristics were investigated. When the target voltage was increased more than 360 V, the signal current increases rapidly and the dark current of the target was suppressed at 3.2 nA up to the voltage of 490 V. And the peak spectral response of the target was obtained at the wavelength of 460 nm. Also the amplitude response of the HARP tube was 7.5% at 800 TV lines, and the decay lag was 3.4%.
Naoki Kakuta,Ryuichi Nakano,Akiyo Nakano,Yuki Suzuki,Ayako Tanouchi,Takashi Masui,Saori Horiuchi,Shiro Endo,Risako Kakuta,Yasuo Ono,Hisakazu Yano 대한진단검사의학회 2020 Annals of Laboratory Medicine Vol.40 No.1
Background: Mutations in the quinolone resistance-determining regions (QRDRs) of Acinetobacter baumannii DNA gyrase (gyrA) and topoisomerase IV (parC) are linked to fluoroquinolone (FQ) resistance. We developed a mismatched PCR-restriction fragment length polymorphism (RFLP) assay to detect mutations in the gyrA and parC QRDRs associated with FQ resistance in A. baumannii. Methods: Based on the conserved sequences of A. baumannii gyrA and parC, two primer sets were designed for mismatched PCR-RFLP to detect mutations in gyrA (codons 83 and 87) and parC (codons 80 and 84) by introducing an artificial restriction enzyme cleavage site into the PCR products. This assay was evaluated using 58 A. baumannii strains and 37 other Acinetobacter strains that have been identified by RNA polymerase β-subunit gene sequence analysis. Results: PCR amplification of gyrA and parC was successful for all A. baumannii strains. In 11 FQ -susceptible strains, the gyrA and parC PCR products were digested by the selected restriction enzymes at the site containing gyrA (codons 83 and 87) and parC (codons 80 and 84). PCR products from 47 FQ-resistant strains containing mutations in gyrA and parC were not digested by the restriction enzymes at the site containing the mutation. As for the non-baumannii Acinetobacter strains, although amplification products for gyrA were obtained for 28 strains, no parC amplification product was obtained for any strain. Conclusions: This assay specifically amplified gyrA and parC from A. baumannii and detected A. baumannii gyrA and parC mutations with FQ resistance.
Akiyo Nakano,Ryuichi Nakano,Yuki Suzuki,Kyoichi Saito,Kei Kasahara,Shiro Endo,Hisakazu Yano 대한진단검사의학회 2018 Annals of Laboratory Medicine Vol.38 No.4
Dear Editor, Carbapenem-resistant Enterobacteriaceae have acquired carbapenemase genes [1], which differ substantially across countries [2]. Transferable carbapenemase IMP-type metallo-β-lactamases, particularly IMP-1 and IMP-6, are commonly identified in the clinical setting in Japan [3, 4] and exhibit different substrate specificity despite having a difference of only one amino acid (IMP-6: Ser214Gly). IMP-1 producers are more resistant to imipenem than to meropenem, whereas IMP-6 producers are more resistant to meropenem [5]. We previously found that the susceptibility rate of IMP-6-positive Escherichia coli was higher for imipenem than for meropenem [3]. Thus, IMP-6-producing isolates may be erroneously categorized as imipenem-susceptible, which could lead to treatment failure in patients.